Monty Pal, MD

Dr. Pal is co-director of the Kidney Cancer Program at City of Hope and head of the kidney and bladder cancer disease team at the institution.

Articles by Monty Pal, MD

Brian Rini, MD, FASCOVideo Insights | March 16, 2023
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
View More
Monty Pal, MDRoundtable | March 15, 2023
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
Monty Pal, MDRoundtable | March 15, 2023
The panel shares how they treat frontline papillary kidney cancer.
Brian Rini, MD, FASCOVideo Insights | March 15, 2023
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
Monty Pal, MDRoundtable | March 14, 2023
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
Brian Rini, MD, FASCOVideo Insights | March 14, 2023
In a debate series between Brian Rini, MD, and Monty Pal, MD, they discuss frontline RCC treatment options.
Monty Pal, MDRoundtable | March 10, 2023
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
Monty Pal, MDRoundtable | March 10, 2023
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
Monty Pal, MDRoundtable | March 9, 2023
The panel discusses outcomes from the CheckMate-9ER trial and addresses the importance depth of response.
Monty Pal, MDRoundtable | March 9, 2023
The panel compares three TKI/IO treatment combinations.
Monty Pal, MDRoundtable | March 9, 2023
The panel discusses considerations for treatment choice in patients with poor- and intermediate-risk disease.
Monty Pal, MDRoundtable | March 1, 2023
A panel discusses 4 frontline RCC treatment options.